secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001356576-26-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance
--------------------------------------------------------------------------------

- Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).
- Qelbree net sales $77.9M (+20%), GOCOVRI $35.2M (+15%), ONAPGO $8.4M, ZURZUVAE collab revenue $27.6M (U.S. sales doubled per Biogen).
- ONAPGO second supplier FDA submission expected Q3 2026; potential approval mid-2027.
- Pipeline: SPN-817 (epilepsy) Phase 2b enrolling; SPN-820 (MDD) Phase 2b ongoing; SPN-443 (ADHD) Phase 1 expected H2 2026.
- Company reiterates full year 2026 financial guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000020/0001356576-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000020/supn-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001356576-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer